GSTM1 and anemia: The presence of anemia (Hb < 10 g/dL) before TAVR did not correlate with 30-day mortality (HR = 1.72, 95% CI [0.96–3.12]; p = 0.073), but it correlated with 1-year mortality (HR = 2.78, 95% CI [1.60–4.82]) [9], as well as 3-year mortality, as reported in a meta-analysis [10].